FDA warning letters and recalls: the lookup guide
Released: · Last reviewed:
Last verified 2026-11-20 · methodology · conflict-of-interest disclosure · dataset: open JSON
Warning letters and recalls on our records (November 20, 2026)
| Date | Recipient | Action | What FDA said |
|---|---|---|---|
| 2026-10-30 (posted 11-03) | RonanRx | Warning letter 737905 | “FDA-Approved Compounded Medications” category, labels naming RonanRx as compounder, “American made” and “$78 a month” video claims |
| 2026-10-30 | Victory Medical Center Pharmacy (TX) | Class II recall (FDA enforcement report, November 11) | Semaglutide and tirzepatide combination vials; lack of processing controls; CO, FL, TX |
| October 2026 | Carolina Infusion, Apothecary Pharma, Houston Rx | Class II recalls (enforcement reports, October 14 and 21) | Lack of assurance of sterility |
| 2026-09-18 | Empower Pharmacy (TX) | Warning letter 738238 | Additive tirzepatide and semaglutide products “essentially copies” of approved drugs; insanitary conditions |
| 2026-06-08 | NexLife | Warning letter 730096 | Website claims false or misleading; labels named NexLife as if it compounded the drugs |
| 2026-06-08 | Eden | Warning letter 728279 | Labels named Eden as if it compounded the drugs; suppliers called “FDA-licensed” |
| 2026-02-20 | MEDVi | Warning letter 721455 | Labels named MEDVi as compounder; “same active ingredient” claims |
Telehealth warning letters to other programs in our dataset
FDA’s warning-letter index listed 114 telehealth warning letters when we read it on November 20, 2026: 56 dated in 2026 for false or misleading claims and 58 dated September 9, 2025, about unlawful online sales of unapproved and misbranded drugs. None had a close-out letter posted. Besides NexLife, Eden and MEDVi above, these went to programs in our dataset:
| Date | Program | Letter (source) | FDA subject | Close-out |
|---|---|---|---|---|
| 2026-06-08 | OrderlyMeds | Warning letter 728291 | False & Misleading Claims/Misbranded (Telehealth) | none posted |
| 2026-02-20 | Ivim Health | Warning letter 721816 | False & Misleading Claims/Misbranded (Telehealth) | none posted |
| 2026-02-20 | Zappy Health | Warning letter 717991 | False & Misleading Claims/Misbranded (Telehealth) | none posted |
| 2026-02-20 | Strut Health | Warning letter 721448 | False & Misleading Claims/Misbranded (Telehealth) | none posted |
| 2026-02-20 | SkinnyRx | Warning letter 717989 | False & Misleading Claims/Misbranded (Telehealth) | none posted |
| 2026-02-20 | Levity | Warning letter 717990 | False & Misleading Claims/Misbranded (Telehealth) | none posted |
| 2026-02-20 | Fifty 410 | Warning letter 721481 | False & Misleading Claims/Misbranded (Telehealth) | none posted |
| 2025-09-09 | Hims (Hims & Hers) | Warning letter 716567 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | none posted |
| 2025-09-09 | Hers (Hims & Hers) | Warning letter 716825 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | none posted |
| 2025-09-09 | Zealthy | Warning letter 716501 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | none posted |
| 2025-09-09 | Sprout Health | Warning letter 715879 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | none posted |
| 2025-09-09 | Direct Meds | Warning letter 716822 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | none posted |
| 2025-09-09 | Remedy Meds | Warning letter 716830 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | none posted |
| 2025-09-09 | Curex | Warning letter 716821 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | none posted |
Our analysis of the RonanRx letter: what FDA’s RonanRx letter says about a $78 price.
A warning letter is FDA’s notice of alleged violations with a deadline to respond; it is not a court finding, a recall or a ban. Check for a close-out letter before treating it as resolved.
The three lookups that answer it yourself
Warning letters: FDA’s searchable warning-letter database — search the pharmacy or company name, read the letter itself (subject lines tell you if it’s sterility, misbranding, or unapproved-drug marketing). Recalls: FDA’s recall and safety-alert listings, searchable by drug name — match lot numbers against your vial. Adverse events: MedWatch, both to search signals and to report your own (1-800-FDA-1088) — reporting is the feedback loop.
FDA’s current GLP-1 concern areas, per its own statements
Unapproved salt forms (semaglutide sodium/acetate) marketed as semaglutide; dosing errors from unit-conversion confusion across compounded concentrations — the reason this site refuses to publish a units calculator; fraudulent and counterfeit product, especially “brand” pens at implausible prices; and mass-marketed “research” peptides (retatrutide included) sold outside any lawful human-use pathway. Each maps to a bright-line test on the legitimacy checklist.
The verified adverse-event figures — with the caveat welded on
As of May 31, 2026, FDA said it had received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide — and FDA itself cautions that reports may be underreported and that a report does not by itself establish that the drug caused the event. Both figures were verified against FDA’s unapproved-GLP-1 concerns page on 2026-08-25. Quote them with the date and the causation caveat, or not at all.
What this desk records, and the standard for publishing it
When an enforcement action names a provider or pharmacy in our dataset, it gets recorded on that provider’s file with a link to the primary FDA document and a date — primary source or it doesn’t publish. This page updates as the dataset does; a blank ledger today means “nothing sourced yet,” never “nothing exists.”
Update log
- 2026-08-26 — Page created per the Pass-12 audit; sources inline.